| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | - | - | - |
| Operating Income | ¥-12.3B | ¥-12.9B | +4.6% |
| Ordinary Income | ¥-12.5B | ¥-13.1B | +4.5% |
| Net Income | ¥-12.5B | ¥-13.1B | +4.5% |
| ROE | -602.9% | -471.8% | - |
FY2026 Q3 results show continued operating losses with some YoY improvement: Operating Loss of 12.3B yen (YoY improvement +4.6% from -12.9B yen loss), Ordinary Loss of 12.5B yen (improvement +4.5% from -13.1B yen), and Net Loss of 12.5B yen (improvement +4.5% from -13.1B yen). The company remains in pre-revenue or early-stage commercialization phase with no disclosed revenue figures. Basic EPS improved to -110.72 yen from -153.93 yen (improvement +28.1%), reflecting reduced per-share losses. Total assets contracted to 3.3B yen from 4.3B yen, while equity decreased to 2.1B yen from 2.8B yen. Cash position declined 29.0% YoY to 2.4B yen from 3.4B yen, indicating ongoing cash consumption. Full-year guidance projects continued losses with Operating Loss of 15.0B yen and Net Loss of 15.1B yen.
Revenue drivers remain undisclosed as sales figures are not reported in the XBRL data, suggesting the company is still in development stage without material commercial revenues. The primary driver of loss reduction appears to be cost management, as operating losses narrowed by 0.6B yen YoY. Non-operating expenses totaled 0.1B yen, minimal in scale, while non-operating income was negligible at 0.01B yen comprising interest income. The gap between operating loss of 12.3B yen and ordinary loss of 12.5B yen reflects net non-operating costs of approximately 0.2B yen, representing minimal variance. Profit before tax matched ordinary income at -12.5B yen with zero income tax expense recorded, typical for loss-making entities with no current tax liability. The improvement in absolute loss from 13.1B yen to 12.5B yen (reduction of 0.6B yen or 4.5%) suggests expense discipline, though without revenue or detailed cost breakdowns, specific drivers cannot be isolated. The accumulated deficit of 111.8B yen in retained earnings highlights prolonged unprofitability. This represents a revenue down or absent/profit up (loss reduction) pattern, though structural profitability remains unachieved.
[Profitability] ROE of -602.9% reflects net losses against diminished equity base and is not meaningful as a performance indicator in the current loss-making stage. No operating margin can be calculated due to absence of revenue disclosure. [Cash Quality] Cash and deposits stand at 2.4B yen, providing coverage of 2.0x against current liabilities of 1.2B yen, indicating adequate short-term liquidity despite the 29.0% YoY cash decline. Working capital of 1.7B yen supports near-term operations. [Investment Efficiency] Asset turnover cannot be calculated without revenue data. Property, plant and equipment totals 0.4B yen, representing 12.3% of total assets, consistent with a development-stage pharmaceutical company with limited physical infrastructure. [Financial Health] Equity ratio of 63.5% demonstrates conservative capitalization with minimal leverage risk. Current ratio of 240.8% significantly exceeds the 100% threshold, confirming strong short-term solvency. Debt-to-equity ratio of 0.58x indicates low financial leverage. Total assets of 3.3B yen decreased 23.3% YoY, primarily driven by cash consumption.
Cash and deposits decreased 1.0B yen YoY to 2.4B yen, representing a 29.0% decline that signals ongoing operational cash burn. With operating losses of 12.3B yen in the nine-month period and accumulated deficit of 111.8B yen, cash outflows are structurally driven by pre-revenue development activities. Current assets declined from 3.9B yen to 2.9B yen YoY, with the cash reduction accounting for the majority of this contraction. Working capital remains positive at 1.7B yen, providing a buffer against short-term obligations of 1.2B yen, yielding cash coverage of 2.0x for current liabilities. The absence of significant non-current liabilities (balance sheet shows only current liabilities of 1.2B yen) suggests minimal long-term debt burden. Asset contraction from 4.3B yen to 3.3B yen reflects cash utilization rather than asset liquidation, as PP&E holdings remained stable at 0.4B yen. The rate of cash consumption at approximately 1.0B yen per nine months, if sustained, implies existing cash would support operations for roughly 18-24 months absent additional funding. No material increases in payables or other working capital items are evident to suggest payment deferrals as a liquidity management tool.
Ordinary loss of 12.5B yen versus operating loss of 12.3B yen shows net non-operating expenses of approximately 0.2B yen, representing 1.6% of the operating loss magnitude and thus immaterial to overall earnings quality assessment. Non-operating expenses of 0.1B yen comprised minor items with negligible foreign exchange losses. Non-operating income of 0.01B yen consisted entirely of interest income, reflecting returns on cash deposits. With no disclosed revenue, non-operating items cannot be expressed as a percentage of sales. The company reported zero income tax expense, consistent with ongoing losses and likely full valuation allowances against deferred tax assets. Without cash flow statement data, the relationship between reported losses and operating cash outflows cannot be verified, limiting assessment of accrual quality. The absence of extraordinary items, impairments, or restructuring charges in the disclosed data suggests reported losses reflect core operational burn rates. The 28.1% improvement in EPS from -153.93 yen to -110.72 yen outpaced the 4.5% improvement in absolute net loss, attributable to an 8.0% increase in average shares outstanding from prior period, partially diluting the per-share improvement.
The company maintains full-year guidance projecting Operating Loss of 15.0B yen, Ordinary Loss of 15.1B yen, and Net Loss of 15.1B yen with EPS of -155.45 yen. Through Q3 (nine months), actual operating loss of 12.3B yen represents 82.0% of the full-year guided loss, suggesting Q4 operating loss of approximately 2.7B yen. This implies a quarterly run rate decline from the 4.1B yen average of the first nine months (12.3B/3), indicating either seasonal improvement or anticipated cost reductions in the final quarter. Ordinary loss progress of 82.7% (12.5B of 15.1B) aligns closely with operating loss progress. The Q3 cumulative progress exceeding 75% is typical for a nine-month reporting period, though the implied Q4 improvement warrants monitoring for sustainability. No guidance revision was disclosed this quarter, indicating management confidence in achieving stated targets. Dividend guidance remains at zero yen, consistent with the loss position and capital preservation priorities. The forecast assumes continued operating losses throughout the fiscal year with no inflection to profitability expected in the near term.
The company maintains a no-dividend policy with both interim and year-end dividends at zero yen for the current fiscal year, unchanged from prior periods. Payout ratio is not applicable given the net loss position. No share buyback programs are disclosed in the available data. The absence of shareholder returns via dividends or buybacks reflects appropriate capital allocation given the company's pre-revenue stage, ongoing operating losses, and declining cash position. Total return ratio is zero as no capital has been returned to shareholders. Retained earnings of -111.8B yen represent substantial accumulated deficits that preclude dividend payments under typical regulatory and prudential constraints. The dividend policy aligns with the company's need to preserve cash for operational requirements and development activities. Future dividend capacity will depend on achieving sustained profitability and rebuilding retained earnings, milestones not anticipated in the current fiscal year guidance.
Cash depletion risk: Cash and deposits declined 29.0% YoY to 2.4B yen while quarterly burn rates average approximately 4.1B yen in operating losses, implying existing cash covers roughly 18-24 months of operations at current burn rates without additional financing. Accumulated deficit of 111.8B yen limits capital cushion for absorbing continued losses or unexpected setbacks.
Revenue generation uncertainty: Absence of disclosed revenues indicates the company remains pre-commercial or in early-stage commercialization. Delayed product approvals, clinical trial failures, or commercialization setbacks could prolong the path to profitability and necessitate additional capital raises, potentially diluting existing shareholders.
Development stage execution risk: With no disclosed R&D expenditures or pipeline details, inability to advance drug candidates through clinical development or obtain regulatory approvals represents existential risk. Pharmaceutical development carries high failure rates and the company's concentrated balance sheet offers limited resilience to pipeline setbacks.
[Industry Position] (Reference - Proprietary Analysis)
Delta-Fly Pharma's financial profile reflects a development-stage pharmaceutical company with characteristics typical of pre-revenue biotech firms. Profitability: ROE of -602.9% compares to industry median of -35.8%, indicating the company's losses are substantially larger relative to its equity base than typical sector peers, consistent with concentrated R&D burn and accumulated deficits. The negative ROE is directionally aligned with the industry median's negative territory, though the magnitude suggests more intensive cash consumption relative to capital base. Financial Health: Equity ratio of 63.5% is below the industry median of 67.8% but within the interquartile range of 62.1%-79.1%, positioning the company in the lower-middle quartile for capitalization strength. Current ratio of 240.8% significantly exceeds the industry median of 6.62x, indicating exceptional short-term liquidity relative to sector norms, though this reflects a smaller absolute scale rather than superior operational strength. Efficiency: Operating margin cannot be calculated due to absent revenue disclosure, limiting direct comparison to the industry median of -218.2%, though the company's stage suggests margins would be deeply negative. Financial leverage of 1.57x aligns closely with the industry median of 1.47x, confirming conservative debt utilization typical of development-stage firms relying primarily on equity financing. The company's EPS improvement of +28.1% YoY contrasts with the industry median EPS growth of -6.0%, representing relative outperformance in loss reduction, though both remain in negative territory. Industry: Pharmaceutical sector development-stage companies (13 companies), Comparison: 2025-Q3 benchmarks, Source: Proprietary analysis.
Loss trajectory shows modest improvement as operating losses narrowed 4.6% YoY to 12.3B yen and EPS losses reduced 28.1% to -110.72 yen, indicating cost management efforts, though structural profitability remains distant without disclosed revenue generation or commercialization timelines. The company maintains strong short-term liquidity with current ratio of 240.8% and cash coverage of 2.0x current liabilities, positioning it to sustain operations in the near term, but the 29.0% YoY cash decline to 2.4B yen signals consumption rates that will necessitate capital raising within 18-24 months absent revenue inflection or further cost reductions. Capital structure remains conservative with equity ratio of 63.5% and debt-to-equity of 0.58x, providing financial flexibility for future financing and limiting bankruptcy risk, though accumulated deficit of 111.8B yen constrains equity buffer and dividend capacity for the foreseeable future.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.